GILOTRIF - (20,30,40 mg; Tablet, Oral)

Generic Name	AFATINIB DIMALEATE	**Innovator**	Boehringer Ingelheim
Dosage	20,30,40 mg; Tablet, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	More Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	Less Than 5	**Generic Launches**	None
Indication	Used to treat people with non-small cell lung cancer (NSCLC) that: has certain (non-resistant) abnormal epidermal growth factor receptor (EGFR) geneY		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.